AdORN: For Ovarian, Fallopian tube, and Peritoneal Cancer - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn whether the investigational drug, atezolizumab, can be given with standard chemotherapy without delaying surgery for ovarian, fallopian tube and peritoneal cancer.
What is the Condition Being Studied?
Ovarian, fallopian tube, and peritoneal cancer

Who Can Participate in the Study?

Adult females who:
- Have not had prior treatment for advanced (stage III or IV) ovarian, fallopian tube, or primary peritoneal cancer
- Are eligible to get neoadjuvant (before surgery) chemotherapy for the treatment of their cancer and will be having one or more surgical procedures

Age Group

What is Involved?

If you agree to be in the study, you will:
- Get a combination of atezolizumab, paclitaxel, and carboplatin every three weeks for nine weeks
- Have surgery, followed by an additional nine weeks of atezolizumab, carboplatin, and paclitaxel

If your cancer does not get worse, you will get atezolizumab in the maintenance setting every three weeks for up to 18 months.

Study Details

Full Title
Atezolizumab in Combination with Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery for Patients with Newly-Diagnosed Advanced-Stage Epithelial Ovarian Cancer
Principal Investigator
Gynecologic Oncologist
Protocol Number
IRB: PRO00079313
NCT: NCT03394885
Phase II
Contact the Duke Recruitment Innovation Center